Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    S&P 500 tumbles 3.7% in worst week since April 2025

    November 21, 2026

    NASA to end Terra satellite mission after decades of work

    November 20, 2026

    Florida flooding rain storm Thanksgiving travel climate hit

    November 19, 2026
    Tucson PatriotTucson Patriot
    • Automotive

      Jaguar Type 01 electric GT debuts with 1,030 PS

      October 7, 2026

      Audi launches Q9 and high performance SQ9 V8 SUV variants

      July 31, 2026

      Ford recalls nearly 420,000 SUVs over seat belt issue

      June 4, 2026

      Mercedes-Benz USA unveils 2027 S-Class with MB.OS tech

      January 30, 2026

      Ford issues US recall for Escape Focus Explorer and Lincoln MKC

      January 22, 2026
    • Business

      S&P 500 tumbles 3.7% in worst week since April 2025

      November 21, 2026

      S&P 500 falls for fourth straight day as Nvidia weighs on stocks

      November 18, 2026

      Brent rises to $93.14 as Gulf attacks keep oil market on edge

      November 18, 2026

      Dollar index climbs to 103.50 as Fed hike bets lift US currency

      November 17, 2026

      Diesel slips to $5.998 a gallon as crude drops and demand eases

      November 16, 2026
    • Entertainment

      Sony confirms God of War trilogy remake and PS5 prequel

      February 13, 2026

      Netflix profit hit by Brazil tax charge despite revenue rise

      October 22, 2025

      Fantastic Four leads with second-biggest opening in 2025

      July 27, 2025

      Disney and Marvel’s R-rated film hits billion-dollar milestone

      August 17, 2024

      Web3 leader Immutable rolls out $50M gaming rewards initiative

      April 27, 2024
    • Health

      Mpox cases top 1,000 in Brazil as first 2026 death confirmed

      November 16, 2026

      Together for Science and Health unites 240 groups behind WHO

      November 11, 2026

      Measles surge in US tops 4,580 as Pennsylvania outbreak grows

      October 26, 2026

      Microsoft AI doubles physician accuracy on complex cases

      October 24, 2026

      Walgreens eye drops included in nationwide sterility recall

      October 5, 2026
    • Lifestyle

      Apple and ISSEY MIYAKE unveil new 3D-knit iPhone Pocket

      November 13, 2025

      JP Morgan funds Fresha with $31 million for AI and robotics growth

      August 23, 2024

      Adidas, Highsnobiety debut limited-edition sneakers

      January 6, 2024

      Unraveling Starbucks’ phenomenon as a worldwide coffee powerhouse

      September 1, 2023

      How Nike’s Kobe 8 Protro Halo Marks an Emotional Milestone

      August 29, 2023
    • Luxury

      Price hikes and lack of innovation erode luxury market confidence

      November 18, 2024

      Uncover the allure of Rolex Deepsea – luxury awaits.

      April 10, 2024

      Beyond timekeeping to the prestige of the Rolex Day-Date

      March 2, 2024

      Rare uncut emerald dazzles at Sharjah show

      February 1, 2024

      Porsche and Frauscher launch the electric 850 Fantom Air

      October 17, 2023
    • News

      Florida flooding rain storm Thanksgiving travel climate hit

      November 19, 2026

      Thousands of US flights disrupted by FAA ground stop

      November 16, 2026

      Thousands of US flights disrupted by FAA ground stop

      November 14, 2026

      Latvia puts AI and drones on UN Security Council agenda

      November 12, 2026

      Guterres calls Ibero-America a cultural superpower in Madrid

      November 6, 2026
    • Sports

      Spain beat Portugal to reach World Cup quarter-finals

      July 7, 2026

      Norway beats Brazil to reach World Cup last eight

      July 6, 2026

      Egypt oust Australia on penalties to reach World Cup last 16

      July 4, 2026

      Spain defeats Austria 3-0 to enter World Cup last 16

      July 3, 2026

      Kane double sends England past Congo DR at World Cup

      July 2, 2026
    • Technology

      NASA to end Terra satellite mission after decades of work

      November 20, 2026

      Apple iPhone Duo delivers the most cohesive foldable yet

      November 2, 2026

      MacBook Pro gets PROLED XDR screen and Touch on Mac

      October 29, 2026

      Integrated Identity Enters Global Top 0.1% with Rare 100/100 Google PageSpeed

      October 29, 2026

      Meta halts Muse chat links after 6,800 found in DNS records

      October 23, 2026
    • Travel

      Holiday travel airfare deals enter peak booking season

      October 3, 2026

      US keeps Belgium at Level 2 in updated travel advisory

      August 6, 2026

      Maine tourism feels strain as Canadian travel drops

      March 30, 2026

      Houston Bush airport warns of four-hour TSA lines

      March 26, 2026

      US winter storm disrupts flights nationwide

      March 17, 2026
    Tucson PatriotTucson Patriot
    Home » BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Provides Update on Phase II Ebola Trial of NV-387 Oral Gummies
    IBN

    BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Provides Update on Phase II Ebola Trial of NV-387 Oral Gummies

    October 5, 2026
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing antiviral drugs, provided additional details on its Phase II clinical trial of NV-387 Oral Gummies for treatment of the current Bundibugyo Ebolavirus “BDBV” outbreak and other Ebola viruses in the Democratic Republic of Congo. The company said the trial is proceeding as designed, with enrollment in Phase IIA beginning on or about Sept. 23, 2026. Phase IIA is intended to identify an optimal, well-tolerated dosing regimen and serve as a go/no-go step before Phase IIB, a randomized controlled trial designed to evaluate efficacy. Pasted markdown

    NanoViricides said NV-387 is designed to attack the virus and reduce viral load and is delivered as an oral gummy that dissolves in the mouth without requiring water or swallowing effort. The company said that, if successful, the oral treatment could be readily deployed in resource-limited settings. NanoViricides characterized NV-387 as a broad-spectrum antiviral that mimics a host-side feature used by Ebola viruses and said there is a rationale for potential activity against Bundibugyo and other Ebola viruses.

    To view the full press release, visit https://ibn.fm/zjg8X

    About NanoViricides

    NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide(TM) class of drug candidates and the nanoviricide(TM) technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

    The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

    Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections, and even Measles. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

    NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

    The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

    NOTE TO INVESTORS: The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC

    About BioMedWire

    BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

    BMW is where breaking news, insightful content and actionable information converge.

    To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

    For more information, please visit https://www.BioMedWire.com

    Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

    BioMedWire
    Austin, Texas
    www.BioMedWire.com
    512.354.7000 Office
    Editor@BioMedWire.com

    BioMedWire is powered by IBN

    Related Posts

    MissionIRNewsBreaks – Versus Systems Inc. (NASDAQ: VS) Expands Filter Fan Cam with New Mobile Augmented-Reality Experience

    November 20, 2026

    TechMediaBreaks – TruGolf Holdings Inc. (NASDAQ: TRUG) Advances Dual-Business Strategy Following Polymath Acquisition

    November 20, 2026

    BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Attention as ‘Men’s Fitness’ Highlights unbuzzd Trial Results

    November 20, 2026

    MissionIRNewsBreaks – AZIO AI Holdings, Inc. (NASDAQ: AZIO) Secures Roles in Two U.S. Army Microgrid Projects Valued at $144.6 Million

    November 20, 2026

    American Fusion(TM) Inc. (AMFN) Reports $1.55 Million in Year-to-Date Financing, Stronger Balance Sheet and IP Portfolio in Q3

    November 20, 2026

    MissionIRNewsBreaks – Massimo Group (NASDAQ: MAMO) Announces January 2027 Launch of Affordable Cove Series Boats

    November 20, 2026
    Latest News

    S&P 500 tumbles 3.7% in worst week since April 2025

    November 21, 2026

    NASA to end Terra satellite mission after decades of work

    November 20, 2026

    Florida flooding rain storm Thanksgiving travel climate hit

    November 19, 2026

    S&P 500 falls for fourth straight day as Nvidia weighs on stocks

    November 18, 2026

    Brent rises to $93.14 as Gulf attacks keep oil market on edge

    November 18, 2026

    Dollar index climbs to 103.50 as Fed hike bets lift US currency

    November 17, 2026
    © 2026 Tucson Patriot | All Rights Reserved
    • Home
    • Contact Us
    • Disclaimer

    Type above and press Enter to search. Press Esc to cancel.